Professor Kamdar is a well respected hematologist oncologist specializing in lymphomas. As an Associate Professor at the University of Colorado Cancer Center, she has made significant contributions to the field through her research and clinical work. Professor Kamdar’s expertise lies in cellular therapies, particularly CAR-T cell therapy targeting CD19. Her studies have demonstrated the effectiveness of CAR-T cell therapies in improving outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma. She has presented her research findings at prominent conferences and is highly respected for her contributions to lymphoma treatment.
About MedAll
MedAll is the fastest growing community of medical professionals and students. Alongside thousands of incredible healthcare organisations and individuals from institutions like Harvard Medical School, Johns Hopkins & Baylor Medical School, we have built an amazing resource of free online medical teaching sessions, conferences and on demand videos that can be accessed anytime:
- Track your CME/CPD
- Learn from the best educators
- Build your CV with certificates of learning
- Prepare for exams, interviews & assessments
We are on a mission to help train millions more healthcare workers by increasing access to great training, reducing travel barriers, providing flexibility around parental or other caring responsibilities and by offering alternative ways to study to support neurodiversity.
Together, we have the power to make change, join us!
Needs Assessment
Clinical Need and Patient-Level Data
Lymphoma is a group of hematological malignancies with distinct clinical presentations and pathological characteristics. According to global data, lymphoma comprises 5% of hematologic malignancies and has a substantial impact on healthcare systems [1].Despite numerous advances, lymphoma remains largely incurable, with relapse or refractoriness posing significant challenges in its management [1].
Diagnosis Gap
The timely and accurate diagnosis of lymphoma is crucial for appropriate management and improved patient outcomes. However, there are challenges in diagnosing lymphomas due to their varied presentations and overlapping symptoms with other conditions. A study published in 2015 found It took a median of 8 weeks for a non-haematology physician to diagnose Diffuse B cell lymphoma and refer to a haematologist [2]. A median of 3 weeks elapsed between specialist consultation and chemotherapy initiation [2]. Common presenting symptoms can be vague and include fatigue, bone pain, anemia, skeletal lesions, hypercalcemia, and elevated serum creatinine levels. This makes it important to close the diagnostic gap in lymphoma crucial to facilitating early detection and enabling timely intervention to improve patient outcomes.
MedAll aims to develop educational initiatives that focus on providing HCPs with the necessary knowledge and skills to effectively diagnose, and manage lymphoma patients. The goal is to bridge this gap to enhance early diagnosis and treatment to enhance the overall experience and outcomes for lymphoma patients.
- Jamil, A., & Mukkamalla, S. K. (2023). Lymphoma. StatPearls. StatPearls Publishing.
- O'Donnell, K., & O'Connor, M. K. (2023). Lymphoma: An overview. British Journal of Haematology, 191(1), 1-11. doi:10.1111/bjh.13150
Declared conflicts of interest
Prof Kamdar has received research funding from Novartis and consultancy fees from AbbVie, AstraZeneca, Celgene/ Bristol-Myers Squibb, Adaptive Biotechnologies, ADC therapeutics, Beigene, Genentech, Syncopation, and Caribou biosciences. She is on the SeaGen speaker's bureau and the data monitoring committees at Celgene and Genentech.